Objectives: Metastasis-associated antigen 1 (MTA1) is implicated in metastasis while 15-lipoxygenase-1 (15-LOX-1) reduces cell motility, when re-expressed in colorectal cancer (CRC). We aimed to understand any potential interplay between MTA1 and 15-LOX-1 in CRC metastasis.
properties, was also shown to be repressed by the NuRD complex in colorectal cancer. 4 MTA1 is highly expressed in a number of normal tissues including murine liver, testes, brain and kidney where the functions of the protein, albeit currently ill defined, may range from regulation of endocytic traffic, oestrogen receptor signalling, regulation of circadian rhythm, mammary gland development, spermatogenesis, macrophage inflammation and liver regeneration following injury. 5 The MTA1 protein is primarily located in the nucleus although it does not have a DNA-binding domain or enzymatic activity. 1 Therefore, most of the functions of MTA proteins are through protein-protein interactions with multi protein regulatory hubs such as the NuRD complex. 6 High MTA1 levels have been unequivocally correlated with poor prognosis and aggressiveness of many different cancer types. 5, 6 Human gastric and colorectal cancers showed significantly higher transcript levels of MTA1 compared to paired normal counterparts. 7 We have previously shown by immunohistochemistry that the expression of MTA1 protein was statistically significantly higher in all human malignant colon tissues resection samples compared to the normal tissues. 8 A number of in vitro and animal studies have also indicated the importance of MTA1 in the metastatic behaviour of cancer cells. 6, 9 15-LOX-1 is a highly regulated enzyme, which preferentially metabolizes linoleic acid to 13-hydroxyoctadecadienoic acid (13-HODE). 10 Multiple lines of evidence collected from various experimental models in different human cancers suggest that 15-LOX-1 plays an anti-tumourigenic role (reviewed in 11 ) and re-expression of 15-LOX-1 was shown to reduce cellular motility in colorectal cancer (CRC). 12, 13 Nuclear factor-kappa B (NF-κB) represents a family of transcription factors of hetero-or homodimers mostly including one subunit of p65 (relA) and another subunit such as p50, c-rel or relB. 14 NF-κB is retained in the cytoplasm in an inactive form by binding to the IκB inhibitory proteins. 15 In the presence of a stimulus, IκB is phosphorylated, which marks it for ubiquitination and degradation, thereby allowing NF-κB translocation into the nucleus, where it can control the transcription of a variety of genes. NF-κB plays important roles in promoting chronic inflammation and tumourigenesis, especially in colon cancer. 16 MTA1 has been shown to be transcriptionally regulated by NF-κB in mice. 17 We and others have shown that re-expression of 15-LOX-1 inhibits the transcriptional activity of NF-κB both in vitro and in vivo. 18, 19 In the current study, we have revisited the role of MTA1 in colorectal cancer. We have analysed publicly available TCGA colorectal cancer RNA-seq data sets as well as microarray data sets and conducted RT-qPCR on human colon cancer cDNA samples to determine the expression of MTA1 and ALOX15. Functionally, MTA1 overexpression in a CRC cell line resulted in reduced cell-cell adhesion. We then examined the hypothesis that the decrease in metastatic potential of 15-LOX-1-expressing CRC cells could be due to the downregulation of MTA1 via 15-LOX-1-mediated inhibition of NF-κB activity. Our data show that the expression of MTA1 was significantly higher in all tumour samples compared to normal samples, irrespective of stage, while the expression of ALOX15 was significantly lower than that of MTA1. A negative correlation between the expression of MTA1 and ALOX15 was seen in two independent microarray data sets as well as in colon cancer cell lines ectopically expressing 15-LOX-1. In the cell lines, this regulation was dependent on NF-κB binding to the MTA1
promoter. Functionally, the re-expression of 15-LOX-1 could reduce the motility of colon cancer cells, through an upregulation of E-cadherin and downregulation of vimentin; this phenotype was rescued when MTA1 was co-expressed.
| MATERIALS AND METHODS

| RNA-seq and microarray data analyses
The RNA-seq by expectation-maximization (RSEM) normalized RNAseq data of colon adenocarcinoma and rectal adenocarcinoma were downloaded from FireHose database FireBrowse facility. 20 The RSEM normalized RNA-seq data of normal tissue were downloaded from the TCGA data portal website (http://cancergenome.nih.gov/) using the data for colon adenocarcinoma and rectal adenocarcinoma.
Log2 transformation was used to standardize the data. Robust
Multiarray Analysis (RMA) normalized data set for GSE39582 was obtained from the NCBI GEO 21 . Data for the C5 subgroup from this data set also were extracted and used for further analysis.
Raw data of GSE41258 were downloaded from the NCBI GEO 22 before performing RMA normalization using gcrma package of Bioconductor. 23 Probesets used for expression data analyses for microarray data sets were as follows: ALOX15: '207328_at'; MTA1:
average of '202247_s_at' and '211783_s_at'. A built-in Matlab function was used to calculate Pearson's correlation between expression values of ALOX15 and MTA1. plotSpread toolbox of Matlab was used to plot the expression data. Matlab was used for ANOVA and F-test analysis. 
| TissueScan array and Real-time qRT-PCR
| Hanging drop assay
To establish whether the overexpression of MTA1 resulted in alterations in cellular adhesion, a hanging drop assay was carried out as described previously with some modifications. 
| Nuclear/cytoplasmic and whole protein extraction
Total protein was isolated using the M-PER protein isolation kit 
| Western blot
| Chromatin immunoprecipitation (ChIP) assay
ChIP assay was carried out as described previously. 8 Briefly, or LoVo cells were grown in 10 cm dishes until confluent and crosslinked with 0.75% paraformaldehyde at room temperature for 7 minutes. Crosslinking was stopped by addition of 2 mmol/L glycine and the cells were collected and washed. Chromatin was sheared to an average size of 500-1000 bp by probe sonication DNA were added to the lysate to isolate the antibody-bound complexes. The beads were washed several times to remove nonspecific binding, and the antibody-bound chromatin was eluted.
The eluate was treated with RNAse A for 1 hour at 37°C and with proteinase K, overnight at 60°C, and finally, the DNA was extracted using Roche High Pure PCR purification kit and used in PCR reactions. Of the final PCR products, 10 μL was electrophoresed on a 2% agarose gel at 100V and photographed under UV light. Primer sequences are shown in Table S1 .
| Bioinformatic analysis of the MTA1 promoter
The promoter region of MTA1 (2000 bases upstream of the +1 site) was analysed with the Alibaba 2.1 program (http://www.generegulation.com/pub/programs/alibaba2/index.html), and based on the putative NF-κB-binding sites, the promoter was divided into two parts. Region I had one NF-κB-binding site, while Region II had five binding sites (Fig. 3a ).
| Construction of reporter plasmids
Region I was cloned as a double-stranded oligonucleotide directly into the multiple cloning site of the pLuc-MCS vector (Stratagene, Santa Clara, CA, USA) and named pLuc-RI. Region II (600 bp) was PCR amplified and cloned into pLuc vector and named as pLuc-RII (oligonucleotide and primer sequences are given in Table S1 ). Both sequences were cloned into the HindIII and XhoI restriction sites and confirmed by sequencing (Sequencing Core Facility, METU Central Lab).
| Luciferase assays
Luciferase assays were carried out using Dual-Glo were used for normalization of the data.
| Electrophoretic mobility shift assay (EMSA)
A non-radioactive EMSA kit (Pierce) was used for this assay. Nuclear proteins were extracted from 15-LOX-1-or empty pcDNA3.1
vector-transfected HT-29 and LoVo cells as described above. NF-κB DNA-binding sequences were designed as three repeats together with their mutated oligos (mainly Gs were converted to As in the original oligo sequences, please see Table S1 for sequences) and of unlabelled oligos (cold probe), which would lead to a loss of the gel shift, whereas for the supershift assay, a p65 monoclonal antibody was used. After mixing with 5X loading dye, the reactants were separated in 8% polyacrylamide gels at 100 V for 1 hour at 4°C and transferred on to Biodyne A or B membranes (Pierce) according to the manufacturer's instructions using electro blotting in 0.5X TBE buffer at 4°C. Subsequently, the membrane was crosslinked with UV and then blocked in streptavidin containing nucleic acid blocking buffer and finally detection was achieved using luminol-enhanced hydrogen peroxide substrate and signals were collected on films by the use of Kodak X-ray film developer machine.
| Motility assay
To understand whether the regulation of MTA1 expression via plasmid. The plasmid was pcDNA3.1 for all transfections. The migration assay was carried out as described previously. 13 Briefly, 5x10 4 cells were counted and pipetted into Transwell inserts in 1% serum containing medium and the inserts were then placed in medium containing 10% serum. The cells were allowed to migrate for 48 hours, after which the inserts were taken and the non- 
| Statistical analysis
Results are expressed as the mean ± SD. One-way ANOVA with
Tukey's post hoc test or Student's t-test were used for statistical analysis, and differences at P<.05 were considered significant.
Experiments were repeated independently at least three times with at least three technical replicates.
| RESULTS
| MTA1 expression is upregulated in tumours compared to normal colon cancer samples
MTA1 has a number of important functions in normal tissues 5 ;
nonetheless, a number of studies have shown that MTA1 is upregulated in many tumours. 1 To reconfirm this upregulation in colorectal cancer, we analysed MTA1 expression using mRNA-sequencing data for colorectal tumours (TCGA COADREAD cohort n=416 with known stages, and normal samples n=50). We observed a significant increase in MTA1 mRNA expression in tumours (Fig. 1a, left irrespective of the stage (Fig. S1A) compared to the normal samples. Corroborating this, an increased expression of MTA1 was observed in tumours compared to normal samples in a human colon cancer cDNA array by RT-qPCR (Fig. 1a, right panel) and two large microarray data sets GSE39582 and GSE41258 (Fig. S1B ).
To detect whether MTA1 overexpression showed any functional effects in colon cancer cell lines, a hanging drop assay was carried out (Fig. 1b) . (Fig. 1d) . In particular, for the data set GSE39582, a specific subgroup of patients defined as C5 showed a stronger negative correlation compared to the other subgroups. No significant negative correlation could be detected between the expression of the two genes in the TCGA RNA-seq data set or the cDNA array (data not shown).
| 15-LOX-1 re-expression downregulates the expression of MTA1 in CRC cell lines
The negative correlation observed in the expression of ALOX15
and MTA1 in human colon tumour samples (Fig. 1d) indicated the presence of a potential crosstalk between 15-LOX-1 and MTA1.
To examine this further, we used colon cancer cell lines (HT-29
and LoVo) that we previously found to highly express MTA1. 8 We have transiently expressed 15-LOX-1 in these cell lines and have observed a reduction in the expression of MTA1 compared to empty vector carrying cells (Fig. 2 ).
| 15-LOX-1 expression reduces the nuclear translocation of NF-κB
We and others have previously shown that 15-LOX-1 expression leads to an inhibition in NF-κB activity. 18, 19 MTA1 is also known to be transcriptionally regulated by NF-κB. 17 We therefore aimed to understand mechanistically whether the inhibition in MTA1 expression observed in the presence of 15-LOX-1 was related to the inhibition of NF-κB. We have previously reported that HT-29 cells ectopically expressing 15-LOX-1 showed reduced nuclear translocation and activity of NF-κB. 18 To confirm whether the same was true in LoVo cells, we carried out a Western blot and observed reduced nuclear translocation of p65 in the cells expressing 15-LOX-1 compared to the empty vector transfected cells.
This was accompanied by increased stability of IκBα, a protein that restrains p65 in the cytoplasm, in the 15-LOX-1-expressing cells (Fig. 3) . The results confirmed that expression of 15-LOX-1 in both HT-29 18 and LoVo (current study) cells could reduce NF-κB translocation when compared to the empty vector carrying cells. The nuclear translocation of p65 in HT-29 cells was also examined in the course of the current study and found to be reproducible (data not shown).
| 15-LOX-1 expression regulates p65 binding to the MTA1 promoter
To identify the NF-κB-binding sites on the MTA1 promoter, ~2 kb sequence upstream of the start site was extracted from the NCBI database and analysed using the Alibaba 2. Three independent experiments were performed and statistical comparisons were carried out using paired t-test (*P < .05) transcription start site (Fig. 4a) . We have also carried out a multiple alignment analysis of the same genomic region on the MTA1 pro- 
| Chromatin immunoprecipitation (ChIP) assay
ChIP followed by PCR was carried out to amplify the region between (Fig. 4b) . As an additional negative control, immunoprecipitated DNA was subjected to PCR amplification by a primer set that amplifies a gene desert region on chromosome 12 and therefore is expected not to have any transcription factor binding (control primer sequences are given in Table S1 ). 15-LOX-1-transfected HT-29 cells showed reduced recruitment of p65 onto both Regions I and II, while LoVo cells showed reduced recruitment only in Region I when compared to the empty vector transfected cells.
| Reporter gene assays
To analyse the transcriptional activity of NF-κB in the MTA1 pro- 
| Electrophoretic mobility shift assay (EMSA)
Non-radioactive EMSA was carried out to establish the binding of NF-κB p65 to the individual sequences identified in Regions I and Table S1 ). The biotin-labelled oligonucleotides 1, 2, 3 and 6 were able to form complexes with proteins from the nuclear extract (Fig. S2) . On further addition of corresponding unlabelled oligonucleotide (cold probe), we observed the disappearance of the shift as evidenced by the ability of excess unlabelled probe to compete with complex formation. The presence of p65 in the shifted complex was confirmed by the addition of a monoclonal p65 antibody, which resulted in a super shift of the complex.
As maximum binding was observed with oligos 1 and 6, the NF-κB binding sequences in these oligos were mutated (see Table S1 for the mutated oligo sequences) and the binding was further validated with nuclear extracts from both HT-29 and LoVo cells (Fig. 4d) . 
| Motility in HCT-116 cells expressing 15-LOX-1 and MTA1
To understand whether the low MTA1 expression observed in CRC cell lines ectopically expressing 15-LOX-1 was functionally relevant, a Transwell migration assay was carried out using HCT-116 cells (Fig. 5a) . HCT-116 cells were used for this purpose as we observed these cells to be more motile than LoVo or HT-29 cells under identical conditions. We have previously reported a reduction in endogenous MTA1 levels as well as a reduction in NF-κB activity in HCT-116 cells stably expressing 15-LOX-1. re-expressing 15-LOX-1, co-expression of 500 ng MTA1 retained the inhibitory effect of 15-LOX-1 on the expression of vimentin (P=.0013).
On the other hand, transfection of 1 μg of the plasmid resulted in a rescue of the phenotype with the cells expressing higher amounts of vimentin, irrespective of whether 15-LOX-1 was expressed or not.
We did not observe significant changes in the expression of E-cadherin in HCT-116 cells with any of the transfections.
To observe whether these functional and molecular changes were also valid in the LoVo cell line model used in the current study, a scratch assay was carried out in these cells transiently expressing 15-LOX-1, MTA1 or a combination of the two plasmids (Fig. 5c ).
Although 
| DISCUSSION
The MTA family of proteins has been associated with a number of hallmarks of cancer, including loss of apoptosis, anchorage independent growth, motility and metastasis, DNA damage response, angiogenesis and chemoresistance. 32 As copy number variations have not been reported for the MTA1 gene, overexpression and mutations are the most common dysregulations observed across different cancer types. 1 This is most likely because MTA1 is transcriptionally upregulated by the oncoprotein MYC. 33 Functionally, many of the effects of MTA1 are through altered expression of target genes or aberrant protein-protein interactions.
32
MTA1 has been shown to be highly expressed in colorectal cancer at both the protein and mRNA levels through immunohistochemistry and PCR and is known to be associated with metastasis. 7, 8, 34, 35 microarray data sets that showed a statistically significant negative correlation between the expression of the two genes, the negative correlation in the GSE39582 array was mostly driven by data from patients who were subcategorized into the group C5. This subcategorization, which was carried out by the authors for better stratification of colon tumours, divided the colon tumours into six categories (C1-C6) based on their transcriptomes. 21 According to KEGG analysis, each of the different subcategories had unique pathways and signalling mechanisms. 21 It was particularly interesting to note that in C5, a significant downregulation in arachidonic and linoleic acid metabolism was seen, along with a significant upregulation of genes involved in the regulation of EMT and cellular communications. 21 In the cohort studied, 27% of the patients belonged to C5; therefore, it is possible that the negative correlation seen between ALOX15 and MTA1 is valid for a specific subset of patients with a specific gene expression sig- ing mesenchymal characteristics and has been considered to be an important marker for EMT. 42 On the other hand, loss of E-cadherin is associated with a loss in cell-cell contact and is frequently associated with not only the metastatic dissemination of cancer cells but can also lead to uncontrolled proliferation through loss of contact inhibition. 43 Reflecting the motility data, we showed for the first time 
